212 related articles for article (PubMed ID: 9251960)
1. Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
Hirota Y; Miyamura K; Hayata T; Miyakawa I
Gynecol Obstet Invest; 1997; 44(1):70-2. PubMed ID: 9251960
[TBL] [Abstract][Full Text] [Related]
2. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
3. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H
J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone.
Pautier P; Rey A; Haie-Meder C; Kerbrat P; Dutel JL; Gesta P; Bryard F; Morice P; Duvillard P; Lhommé C
Int J Gynecol Cancer; 2004; 14(6):1112-7. PubMed ID: 15571617
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing JA; Malfetano JH
Gynecol Oncol; 1996 Aug; 62(2):226-9. PubMed ID: 8751554
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.
Hawkins RE; Wiltshaw E; Mansi JL
Cancer Chemother Pharmacol; 1990; 26 Suppl():S26-9. PubMed ID: 2347045
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
Pautier P; Genestie C; Fizazi K; Morice P; Mottet C; Haie-Meder C; Le Cesne A; Lhommé C
Int J Gynecol Cancer; 2002; 12(6):749-54. PubMed ID: 12445254
[TBL] [Abstract][Full Text] [Related]
8. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma.
Yeh KH; Lu YS; Hsiao CH; Cheng AL
Anticancer Res; 2003; 23(6D):5133-7. PubMed ID: 14986591
[TBL] [Abstract][Full Text] [Related]
9. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
Piura B; Rabinovich A
Eur J Gynaecol Oncol; 2005; 26(3):275-8. PubMed ID: 15991525
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
12. Hysteroscopic resection of uterine leiomyosarcoma: a case report and literature review.
Nappi L; Di Spiezio Sardo A; Indraccolo U; Bettocchi S
J Minim Invasive Gynecol; 2008; 15(3):380-3. PubMed ID: 18439518
[TBL] [Abstract][Full Text] [Related]
13. Gynecologic Oncology Group experience with ifosfamide.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1990 Apr; 17(2 Suppl 4):6-10. PubMed ID: 2159188
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Edmonson JH; Blessing JA; Cosin JA; Miller DS; Cohn DE; Rotmensch J
Gynecol Oncol; 2002 Jun; 85(3):507-10. PubMed ID: 12051882
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
Pautier P; Floquet A; Gladieff L; Bompas E; Ray-Coquard I; Piperno-Neumann S; Selle F; Guillemet C; Weber B; Largillier R; Bertucci F; Opinel P; Duffaud F; Reynaud-Bougnoux A; Delcambre C; Isambert N; Kerbrat P; Netter-Pinon G; Pinto N; Duvillard P; Haie-Meder C; Lhommé C; Rey A
Ann Oncol; 2013 Apr; 24(4):1099-104. PubMed ID: 23139262
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Barrett RJ; McGehee R
Am J Obstet Gynecol; 1992 Feb; 166(2):556-9. PubMed ID: 1536229
[TBL] [Abstract][Full Text] [Related]
17. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S; Dizdar O; Karakas Y; Turker A; Kars A
Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
[TBL] [Abstract][Full Text] [Related]
19. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
